back to

Back to video list

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Speaker

Alison Moskowitz

Session

Relapsed & Refractory HL

Others Talks of this Session

Updated approach to second-line treatment
Emerging strategies to overcome anti-PD1 resistance
Implementing raditoherapeutic concepts in rrHL care
Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.
Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients